CCO Official Conference Coverage: Clinical Impact of New HIV Data From AIDS 2022

Download All
July 29-August 2, 2022; Montreal, Quebec
Engage in this scientific analysis of data presented at AIDS 2022, with rapid postconference webinars by expert faculty and Capsule Summaries on key HIV prevention, treatment studies,and new and investigational ART regimens. Watch the on-demand webinars, download the slides, and gain global perspectives with companion ClinicalThought commentaries.
Sharon R. Lewin, AO, FRACP, PhD, FAHMS
Chloe Orkin Photo
Chloe Orkin, MBChB, FRCP, MD
Babafemi Taiwo, MBBS
David A. Wohl, MD

Highlights

Slidesets HPTN 083: Safety, Efficacy, and Gender-Affirming Hormonal Therapy Interactions With Long-Acting Injectable CAB for HIV PrEP in Transgender Women
Slidesets NAMSAL: Wk 192 Results of Dolutegravir-Based vs Low-Dose Efavirenz-Based Regimens as First-line ART in Cameroon
Slidesets SIMPL’HIV Wk 144 Results: Dolutegravir + Emtricitabine vs Standard Combination ART for Maintenance of Virologic Suppression
Slidesets ALLIANCE: Phase III Randomized Controlled Trial of BIC/FTC/TAF vs DTG + FTC/TDF in Treatment-Naive Adults With HIV/HBV Coinfection
Slidesets ANDES: Generic Fixed-Dose DRV/RTV in Combination With 3TC vs 3TC/TDF for Initial HIV Treatment
Slidesets TB-PRACTECAL: Efficacy and Safety of Three 24-Wk Oral Regimens for Pulmonary Rifampicin-Resistant TB in Persons With HIV
Slidesets Effect of 6-Mo PrEP Dispensing Plus HIV Self-Testing on 12-Mo PrEP Continuation
Slidesets IMPAACT 2008: Broadly Neutralizing Antibody VRC01 Plus ART in Infants With HIV
Slidesets DoxyPEP: Prevention of STIs With Doxycycline PEP Among MSM and TGW With HIV or Receiving PrEP
Slidesets HPTN 084 Update: Long-Acting Injectable CAB vs Daily Oral TDF/FTC for HIV PrEP in Cisgender Women

Dr Sharon R. Lewin, incoming President of the International AIDS Society, provides an overview of the most clinically exciting papers to be presented at the upcoming conference.

Sharon R. Lewin, AO, FRACP, PhD, FAHMS Released: July 13, 2022

Read expert faculty members’ summaries of key HIV studies from AIDS 2022, including results from studies of prevention strategies, oral therapies, long-acting therapies, cure, and comorbidities.

Chloe Orkin Photo Chloe Orkin, MBChB, FRCP, MD Babafemi Taiwo, MBBS David A. Wohl, MD Released: August 17, 2022

 

 

 

Conference organizers are using social media to communicate with delegates attending the meeting.

Social Media
Join the #AIDS2022 conversation

  

Facebook, Twitter, Instagram, LinkedIn

For more information about these resources and IAS 2022, go to www.aids2022.org.

NAM is the official provider of online scientific news reporting for the conference.

To view the coverage and to sign up for the bulletins, go to https://www.aidsmap.com/conferences/aids-2022.

Conference News – Reported by NAM

Provided by Clinical Care Options, LLC
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Produced in collaboration with
Supported by educational grants from
Gilead Sciences, Inc.
ViiV Healthcare

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings